Skip to main content
Premium Trial:

Request an Annual Quote

Genaissance Shares Begin Clawing Back to Pre-downgrade Levels

NEW YORK, Nov. 2 (GenomeWeb News) - Shares in Genaissance came close to regaining the market share they lost late last month after the company lowered by 20 percent its year-end revenue expectations.


The stock was up 11.5 percent, or $.20, at $2.01 in late-afternoon trade on the Nasdaq exchange after sliding to $2.26 from $2.43 on Oct. 22 following the company's announcement on Oct. 21 that 2004 revenues would fall to between $20 million and $21 million. It was the first day that Genaissance's shares were up since the 7-day decline began.


Genaissance attributed the fall-off in revenue to a delay in certain anticipated contracts and samples associated with some of these contracts. "Our business is partly influenced by our customers' drug development timelines that can cause a delay in the timing of revenues," Kevin Rakin, Genaissance president and CEO, said in a statement on Oct. 21. "Overall, we believe we can grow our revenue in 2005 in excess of 20 percent over 2004."


Recurring operating expenses for the second half of the year will be similar to those in the first half, adjusting for the second-quarter acquisition of Lark and other non-recurring charges, Genaissance said.

The firm will announce its third-quarter earnings on Nov. 9.

The Scan

Billions for Antivirals

The US is putting $3.2 billion toward a program to develop antivirals to treat COVID-19 in its early stages, the Wall Street Journal reports.

NFT of the Web

Tim Berners-Lee, who developed the World Wide Web, is auctioning its original source code as a non-fungible token, Reuters reports.

23andMe on the Nasdaq

23andMe's shares rose more than 20 percent following its merger with a special purpose acquisition company, as GenomeWeb has reported.

Science Papers Present GWAS of Brain Structure, System for Controlled Gene Transfer

In Science this week: genome-wide association study ties variants to white matter stricture in the brain, and more.